

Anti-TNFRSF10B/TRAILR2/CD262 Antibody (Tigatuzumab)

Introduction

Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targeting death receptor 5 (DR5). Tigatuzumab can induce apoptosis in cancer cells and inhibit tumor growth in vivo. Tigatuzumab can be used in cancer research.

Product parameters

Alternative Names	CS-1008, TRA-8, DS-8273
Target Accession	O14763
Target	TNFRSF10B / TRAILR2 / CD262
CAS number	918127-53-4
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	-
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

